Showing results (401-410 of 2,158) with videos related to

Sort By:
Pageof 216
Journal of Biopharmaceutical Statistics|April 7, 2016
Optimal two-stage log-rank test for randomized phase II clinical trialsMinjung Kwak, Sin-Ho Jung
Journal of Biopharmaceutical Statistics|October 27, 2017
Model selection based on combined penalties for biomarker identificationEleni Vradi, Werner Brannath, Thomas Jaki, et al.
Journal of Biopharmaceutical Statistics|October 12, 2017
Bayesian additive decision trees of biomarker by treatment interactions for predictive biomarker detection and subgroup identificationYang Zhao, Wei Zheng, Daisy Y Zhuo, et al.
Journal of Biopharmaceutical Statistics|September 19, 2017
A decision theoretical modeling for Phase III investments and drug licensingFrank Miller, Carl-Fredrik Burman
Journal of Biopharmaceutical Statistics|September 1, 2017
A Bayesian adaptive design for cancer phase I trials using a flexible range of dosesMourad Tighiouart, Galen Cook-Wiens, André Rogatko
Journal of Biopharmaceutical Statistics|September 2, 2017
Time-dependent ROC analysis for censored biomarker data due to limit of detectionYeonhee Kim, Lan Kong
Journal of Biopharmaceutical Statistics|September 6, 2017
Considerations for pediatric trial designs and analysesMeehyung Cho, Zhiying Qiu, Jenny Ye, et al.
Journal of Biopharmaceutical Statistics|November 6, 2014
A Dose-Finding Method Based on Multiple Dosing in Two-Agent Combination Phase I TrialsYasuyuki Kakurai, Akihiro Hirakawa, Chikuma Hamada
Journal of Biopharmaceutical Statistics|November 6, 2014
Sequentially updating the likelihood of success of a Phase 3 pivotal time-to-event trial based on interim analyses or external informationKaspar Rufibach, Paul Jordan, Markus Abt
Pageof 216